The final analysis of the CATNON trial is now published in The Lancet Oncology.

This landmark study helps define a new standard of care for patients with 1p/19q non-codeleted anaplastic glioma, building on results presented at #EANO2025.

🔗 https://ow.ly/WpKF50XWa0G

#EORTC #CATNON #NeuroOncology

Final results from the #CATNON trial by Martin van den Bent et al. have been published in @thelancetoncol.bsky.social, reporting on concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (EORTC 26053-22054).
👉 doi.org/10.1016/S147...
#NeuroOncology #Glioma @eortc.org

🚨 Big news from #EANO2025!

Final #CATNON results show adding 12 cycles of temozolomide after radiotherapy doubles survival in IDH-mutant anaplastic astrocytoma: 12.5 vs 6 years.

🌍 A global academic effort in rare cancers.

🔗 Full story: www.eortc.org/blog/2025/10...

@eanoassociation.bsky.social

Still 2 days to #EANO2025! Congratulations to @martinvandenbent.bsky.social, selected for the Best Oral Presentation Award in Clinical research! He’ll present results of the @eortc.org #CATNON trial in Session OS04 on Sat, Oct 18. 👉 www.eano.eu/eano2025/pro...
#BrainTumor #btsm